Warfarin

is prescribed to treat:

• Preventing and treating blood clots, reducing stroke risk in atrial fibrillation • Various related conditions in the cardiovascular category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Warfarin (Coumadin, Jantoven) is a vitamin K antagonist used to prevent and treat deep vein thrombosis and pulmonary embolism, to prevent stroke in atrial fibrillation, and after mechanical heart valve replacement. Direct oral anticoagulants have displaced it for most indications, but warfarin remains irreplaceable in several settings and is still taken by a very large number of patients.

Mechanism of Action

Warfarin inhibits vitamin K epoxide reductase, the enzyme that regenerates reduced vitamin K. Reduced vitamin K is required to carboxylate clotting factors II, VII, IX, and X, and without carboxylation those factors are synthesised but functionally inactive.

Two consequences follow. First, warfarin has no effect on already-circulating clotting factors, so the anticoagulant effect appears only as existing factors are cleared — full effect takes several days despite the INR rising sooner. Second, warfarin also inhibits carboxylation of proteins C and S, which are natural anticoagulants with shorter half-lives than the procoagulant factors. Their earlier depletion creates a transient hypercoagulable state in the first days of therapy. This is why acute thrombosis is treated with overlapping heparin until the INR is therapeutic, and why warfarin is never started alone in an acute clot.

Warfarin's narrow therapeutic index and extensive interactions stem from its metabolism by CYP2C9 and its dependence on dietary vitamin K. Genetic variation in CYP2C9 and in the VKORC1 enzyme target accounts for much of the wide variation in dose requirement between patients — some need a fraction of what others do.

Clinical Use

Warfarin remains the required anticoagulant for mechanical heart valves, where direct oral anticoagulants have been shown to be inferior and are contraindicated. It is also preferred in moderate-to-severe mitral stenosis, in antiphospholipid syndrome, and in severe kidney impairment where DOAC dosing becomes unreliable. It is far less expensive, which matters for some patients.

For most other indications — non-valvular atrial fibrillation, and treatment of venous thromboembolism — apixaban and rivaroxaban are now generally preferred, because they require no routine monitoring, have fewer food and drug interactions, and carry lower intracranial bleeding risk. A patient on warfarin for one of these indications is reasonably asked whether a DOAC would suit them better, though stable, well-controlled patients who prefer to stay on warfarin are entirely reasonable to continue.

Diet is a source of persistent confusion. The goal is consistency, not avoidance. Patients are frequently told to stop eating leafy greens, which is wrong and nutritionally counterproductive; the correct advice is to keep vitamin K intake roughly steady week to week so the dose can be matched to it. The DVT and travel article covers clot risk in a population where this comes up often, and our hematology team manages the more complex anticoagulation decisions.

Monitoring and Follow-Up

INR monitoring defines warfarin therapy. The usual target range is 2.0 to 3.0 for atrial fibrillation and venous thromboembolism, and higher for most mechanical valves. Testing is frequent during initiation and after any dose change, extending to every four to twelve weeks once a patient is reliably stable.

Time in therapeutic range is the metric that best predicts outcomes — a patient whose INR is in range most of the time does well, while one who swings above and below accumulates both bleeding and clotting risk even if the average looks acceptable. Persistently poor control is itself an argument for switching to a DOAC.

Interactions are numerous enough that the practical rule is to check before starting anything new, including over-the-counter products and supplements. Antibiotics are the most common precipitant of a sudden INR rise, partly through CYP inhibition and partly by disrupting gut flora that produce vitamin K. Amiodarone, fluconazole, and metronidazole raise INR substantially. NSAIDs and aspirin add bleeding risk without changing the INR at all, which makes them easy to overlook. The MedlinePlus warfarin entry lists the interaction profile, and the National Blood Clot Alliance provides patient-level guidance on living with anticoagulation.

Special Populations

Warfarin is contraindicated in pregnancy, where it is teratogenic and crosses the placenta; low-molecular-weight heparin is used instead. It is compatible with breastfeeding.

In older adults, dose requirements are lower and bleeding risk is higher, but age alone is not a reason to withhold anticoagulation — the stroke risk in untreated atrial fibrillation rises with age faster than the bleeding risk does, and undertreatment of elderly patients is a more common error than overtreatment. Falls risk is frequently overstated as a contraindication. In liver disease, both synthesis of clotting factors and warfarin metabolism are impaired, making INR interpretation difficult and control unstable.

Reversal is worth understanding in advance. Vitamin K reverses warfarin over hours, and prothrombin complex concentrate does so within minutes for major bleeding or urgent surgery — an established pathway that has existed far longer than the reversal agents for direct oral anticoagulants. For a patient facing frequent procedures, or one whose bleeding risk makes rapid reversibility a priority, that predictability is a real point in warfarin's favour. Minor procedures including most dental work and cataract surgery generally do not require stopping warfarin at all, and interrupting it unnecessarily carries its own thrombotic risk.

When to Contact Your Doctor

Seek emergency care for any head injury, even without immediate symptoms, and for severe or persistent headache, sudden weakness, confusion, or vision change, which may indicate intracranial bleeding. Report black or tarry stools, vomiting blood or material resembling coffee grounds, red or brown urine, coughing up blood, or bleeding that will not stop with pressure. Unusual bruising, prolonged nosebleeds, or unusually heavy menstrual bleeding warrant an INR check. Always tell any clinician, dentist, or surgeon that you take warfarin before a procedure, and check before starting any new medication or supplement.

To review your anticoagulation, discuss whether a direct oral anticoagulant would suit you better, or address unstable INRs, contact us or schedule a visit.